参考文献:
[1]Rubin DT,Ananthakrishnan AN,Siegel CA,et al.ACG Clinical Guideline:Ulcerative Colitis in Adults.Am J Gastroenterol.2019 Mar;114(3):384-413.
[2]Feuerstein JD,Isaacs KL,Schneider Y,et al.AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis.Gastroenterology.2020 Apr;158(5):1450-1461.
[3]FEAGAN BG,RUTGEERTS P,SANDS BE,et al.GEMINI 1 Study Group.Vedolizumab as induction and maintenance therapy for ulcerative colitis.N Engl J Med,2013,369(8):699-710.
[4]SANDS BE,PEYRIN-BIROULET L,LOFTUS EV JR,et al.VARSITY Study Group.Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis.N Engl J Med,2019,381(13):1215-1226
[5]JAIRATH V,CHAN K,LASCH K,et al.Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments:a net-
work meta-analysis.Expert Rev Gastroenterol Hepatol,2021,15(6):711-722.
[6]李慧博,刘芳,翟所迪.炎症性肠病治疗的新选择:肠道选择性整合素抑制剂维得利珠单抗.中国新药杂志2021,30(20):1841-1845
[7]COLOMBEL JF,SANDS BE,RUTGEERTS P,et al.The safety of vedolizumab for ulcerative colitis and Crohn’s disease.Gut,2017,66(5):839-851.
[8]LUKIN D,WEISS A,ANIWAN S,et al.DOP009 Comparative safety profile of vedolizumab and tumour necrosis factor-antagonist therapy for inflammatory bowel disease:a multicentre consortium propensity score-matched analysis[J].J Crohns Colitis,2018,12(Suppl 1):S036.
[9]Fillman H,Riquelme P,Sullivan PD,Mansoor AM.Aseptic abscess syndrome.BMJ Case Rep.2020;13(10):e236437.
[10]Antonelli E,Bassotti G,Tramontana M,et al.Dermatological Manifestations in Inflammatory Bowel Diseases.J Clin Med.2021;10(2):364.
[11]Yamaguchi Y,Nakagawa M,Nakagawa S,et al.Rapidly Progressing Aseptic Abscesses in a Patient with Ulcerative Colitis.Intern Med.2021;60(5):725-730.
[12]Bollegala N,Khan R,Scaffidi MA,et al.Aseptic Abscesses and Inflammatory Bowel Disease:Two Cases and Review of Literature.Can J Gastroenterol Hepatol.2017;2017:5124354.
[13]Shibuya T,Haga K,Saeki M,et al.Pyoderma gangrenosum in an ulcerative colitis patient during treatment with vedolizumab responded favorably to adsorptive granulocyte and monocyte apheresis.J Clin Apher.2020;35(5):488-492.
[14]Feagan BG,Sandborn WJ,Colombel JF,et al.Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment:Post Hoc Analyses of the GEMINI Trials.J Crohns Colitis.2019;13(1):50-57.
[15]Hanzel J,Ma C,Casteele NV,Khanna R,Jairath V,Feagan BG.Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease[published correction appears in Drugs.2021 Aug 28;:].Drugs.2021;81(3):333-347.